Ezetimibe jama

Jun 18, 2008 At that time, ezetimibe became available, with the potential for even greater reductions of LDL-C. We hypothesized that this would lead to even Mar 21, 2014 Although ENHANCE has not derailed ezetimibe prescribing, the newest cholesterol management guidelines just might. The guidelines, issued

JAMA Intern Med. 2014 Sep174(9):1486-93. doi: 10.1001jamainternmed. 2014.3404. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010

JAMA. 2014 Apr 2311(13):1279-80. doi: 10.1001jama.2014.2896. Ezetimibe prescribing fails to keep up with evidence. Mitka M. PMID: 24647479 PubMed Effect of evolocumab or ezetimibe added to moderate or high-intensity statin therapy Abstract: https:jama.jamanetwork.comarticle.aspxarticleid1869210 May 14, 2014 Research from JAMA Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients

JAMA The ENHANCE Study and Marketing Ezetimibe

Apr 2, 2014 News from JAMA Ezetimibe Prescribing Fails to Keep Up With Evidence. Ezetimibe is an intestinal cholesterol absorption inhibitor found to 2014 May 14311(18):1870-82. doi: 10.1001jama.2014.4030. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C

Aug 5, 2014 Also in JAMA Internal Medicine are two papers by Dr. Joseph Ross of Yale, The first one tracks the continuing use of ezetimibe in the United Research from JAMA Internal Medicine Trends in Use of Ezetimibe After the Initiation was defined as an ezetimibe claim without another in the prior 180